Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

A Population-based Study Showing Better Renal Prognosis for Proteinase 3 Antineutrophil Cytoplasmic Antibody (ANCA)–associated Nephritis Versus Myeloperoxidase ANCA–associated Nephritis

Aladdin J. Mohammad and Mårten Segelmark
The Journal of Rheumatology July 2014, 41 (7) 1366-1373; DOI: https://doi.org/10.3899/jrheum.131038
Aladdin J. Mohammad
From the Department of Clinical Sciences, Section of Rheumatology, Lund University; Department of Rheumatology, Skåne University Hospital, Lund; Department of Nephrology UHL, Östergötland County Council; and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Aladdin.mohammad@med.lu.se
Mårten Segelmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

REFERENCES

  1. 1.↵
    1. Mohammad AJ,
    2. Jacobsson LT,
    3. Westman KW,
    4. Sturfelt G,
    5. Segelmark M
    . Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology 2009;48:1560–5.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Watts RA,
    2. Scott DG,
    3. Jayne DR,
    4. Ito-Ihara T,
    5. Muso E,
    6. Fujimoto S,
    7. et al.
    Renal vasculitis in Japan and the UK—are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 2008;23:3928–31.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Jennette JC,
    2. Falk RJ,
    3. Bacon PA,
    4. Basu N,
    5. Cid MC,
    6. Ferrario F,
    7. et al.
    2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1–11.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Lyons PA,
    2. Rayner TF,
    3. Trivedi S,
    4. Holle JU,
    5. Watts RA,
    6. Jayne DR,
    7. et al.
    Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214–23.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Lionaki S,
    2. Blyth ER,
    3. Hogan SL,
    4. Hu Y,
    5. Senior BA,
    6. Jennette CE,
    7. et al.
    Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452–62.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Mohammad AJ,
    2. Jacobsson LT,
    3. Mahr AD,
    4. Sturfelt G,
    5. Segelmark M
    . Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology 2007;46:1329–37.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Statistics Sweden
    . Population data. [Internet. Accessed April 28, 2014.] Available from: www.scb.se
  8. 8.↵
    1. Watts R,
    2. Lane S,
    3. Hanslik T,
    4. Hauser T,
    5. Hellmich B,
    6. Koldingsnes W,
    7. et al.
    Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222–7.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Luqmani RA,
    2. Bacon PA,
    3. Moots RJ,
    4. Janssen BA,
    5. Pall A,
    6. Emery P,
    7. et al.
    Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671–8.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Franssen C,
    2. Gans R,
    3. Kallenberg C,
    4. Hageluken C,
    5. Hoorntje S
    . Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 1998;244:209–16.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Jennette JC,
    2. Wilkman AS,
    3. Falk RJ
    . Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 1989;135:921–30.
    OpenUrlPubMed
  12. 12.↵
    1. Weidner S,
    2. Geuss S,
    3. Hafezi-Rachti S,
    4. Wonka A,
    5. Rupprecht HD
    . ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004;19:1403–11.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Hogan SL,
    2. Nachman PH,
    3. Wilkman AS,
    4. Jennette JC,
    5. Falk RJ
    . Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23–32.
    OpenUrlAbstract
  14. 14.↵
    1. de Lind van Wijngaarden RA,
    2. Hauer HA,
    3. Wolterbeek R,
    4. Jayne DR,
    5. Gaskin G,
    6. Rasmussen N,
    7. et al.
    Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006;17:2264–74.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Schonermarck U,
    2. Lamprecht P,
    3. Csernok E,
    4. Gross WL
    . Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology 2001;40:178–84.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Geffriaud-Ricouard C,
    2. Noel LH,
    3. Chauveau D,
    4. Houhou S,
    5. Grunfeld JP,
    6. Lesavre P
    . Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993;39:125–36.
    OpenUrlPubMed
  17. 17.↵
    1. Falk RJ,
    2. Hogan S,
    3. Carey TS,
    4. Jennette JC
    . Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990;113:656–63.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Franssen CF,
    2. Gans RO,
    3. Arends B,
    4. Hageluken C,
    5. ter Wee PM,
    6. Gerlag PG,
    7. et al.
    Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease. Kidney Int 1995;47:193–9.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Westman KW,
    2. Bygren PG,
    3. Olsson H,
    4. Ranstam J,
    5. Wieslander J
    . Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842–52.
    OpenUrlAbstract
  20. 20.↵
    1. de Joode AA,
    2. Sanders JS,
    3. Stegeman CA
    . Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013;8:1709–17.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Hauer HA,
    2. Bajema IM,
    3. van Houwelingen HC,
    4. Ferrario F,
    5. Noel LH,
    6. Waldherr R,
    7. et al.
    Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002;61:80–9.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Mohammad AJ,
    2. Bakoush O,
    3. Sturfelt G,
    4. Segelmark M
    . The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI). Scand J Rheumatol 2009;38:268–75.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Berden AE,
    2. Ferrario F,
    3. Hagen EC,
    4. Jayne DR,
    5. Jennette JC,
    6. Joh K,
    7. et al.
    Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010;21:1628–36.
    OpenUrlAbstract/FREE Full Text
  24. 24.
    1. Vizjak A,
    2. Rott T,
    3. Koselj-Kajtna M,
    4. Rozman B,
    5. Kaplan-Pavlovcic S,
    6. Ferluga D
    . Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis 2003;41:539–49.
    OpenUrlCrossRefPubMed
  25. 25.
    1. Rihova Z,
    2. Jancova E,
    3. Merta M,
    4. Rysava R,
    5. Reiterova J,
    6. Zabka J,
    7. et al.
    Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney Blood Press Res 2005;28:144–52.
    OpenUrlCrossRefPubMed
  26. 26.
    1. Flossmann O,
    2. Berden A,
    3. de Groot K,
    4. Hagen C,
    5. Harper L,
    6. Heijl C,
    7. et al.
    Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488–94.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 7
1 Jul 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Population-based Study Showing Better Renal Prognosis for Proteinase 3 Antineutrophil Cytoplasmic Antibody (ANCA)–associated Nephritis Versus Myeloperoxidase ANCA–associated Nephritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Population-based Study Showing Better Renal Prognosis for Proteinase 3 Antineutrophil Cytoplasmic Antibody (ANCA)–associated Nephritis Versus Myeloperoxidase ANCA–associated Nephritis
Aladdin J. Mohammad, Mårten Segelmark
The Journal of Rheumatology Jul 2014, 41 (7) 1366-1373; DOI: 10.3899/jrheum.131038

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
A Population-based Study Showing Better Renal Prognosis for Proteinase 3 Antineutrophil Cytoplasmic Antibody (ANCA)–associated Nephritis Versus Myeloperoxidase ANCA–associated Nephritis
Aladdin J. Mohammad, Mårten Segelmark
The Journal of Rheumatology Jul 2014, 41 (7) 1366-1373; DOI: 10.3899/jrheum.131038
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

ANTINEUTROPHIL CYTOPLASMIC ANTIBODY
GLOMERULONEPHRITIS
VASCULITIS
SURVIVAL
ENDSTAGE RENAL DISEASE

Related Articles

Cited By...

More in this TOC Section

  • Pain Mechanisms Associated With Disease Activity in Patients With Rheumatoid Arthritis Treated With Disease-Modifying Antirheumatic Drugs: A Regression Tree Analysis
  • Immunosuppressive Therapies in Ear, Nose, and Throat Involvement in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Results From a Multicenter Retrospective Cohort Study
  • Work-Related Issues and Physical and Psychological Burden in Canadian Patients With Axial Spondyloarthritis: Results From the International Map of Axial Spondyloarthritis
Show more Article

Similar Articles

Keywords

  • ANTINEUTROPHIL CYTOPLASMIC ANTIBODY
  • glomerulonephritis
  • vasculitis
  • survival
  • endstage renal disease

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire